Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

Abbott Shares Slump as Revenue Miss and Exact Sciences Acquisition Jitters Overshadow Earnings Beat

Topics Economy

January 22, 2026

Abbott Laboratories (NYSE: ABT) saw its shares retreat by 5.8% in early trading on Thursday, January 22, 2026, following the release of its fourth-quarter financial results. Despite delivering an...

Genentech More than Doubles Investment in Holly Springs, North Carolina Manufacturing Facility

Topics Earnings Economy

January 20, 2026

From Genentech

As of January 19, 2026, the pharmaceutical landscape is being redefined by a single name: Eli Lilly and Company (NYSE: LLY). Once a steady, century-old stalwart known for its dominance in the insulin...

The Trillion-Dollar Pharmacopeia: Eli Lilly’s (LLY) Dominance in the Age of Incretins

January 19, 2026

Via Finterra

Topics Economy

Amgen at the Crossroads: MariTide, Market Volatility, and the Quest for Obesity Dominance

January 13, 2026

Date: January 13, 2026 Introduction Amgen Inc. (NASDAQ: AMGN) finds itself at a historic crossroads. Long regarded as the "blue-chip" anchor of the biotechnology sector, the Thousand Oaks-based giant...

Cashing In at the Peak: Olema Pharmaceuticals Insiders Sell $8 Million in Stock After 300% Surge

Topics Economy Intellectual Property

January 09, 2026

Olema Pharmaceuticals (NASDAQ:OLMA) has become the latest focal point of biotech volatility and executive opportunism. Following a staggering 300% surge in its share price over the past year—fueled by...

MoonLake Immunotherapeutics Surges as FDA "De-Risks" Sonelokimab, Reigniting Multi-Billion Dollar Takeover Speculation

January 09, 2026

MoonLake Immunotherapeutics (NASDAQ: MLTX) shares have experienced a dramatic resurgence this week, climbing over 40% following a pivotal regulatory update that has effectively cleared the path for its...

Topics Intellectual Property

J&J Cuts Deal With Trump’s White House To Slash Drug Prices And Dodge Tariffs ↗

January 08, 2026

The Trillion-Dollar Treatment: Eli Lilly Solidifies Dominance as Obesity Drug Boom Enters New Era

Topics Government

January 07, 2026

As the calendar turns to early 2026, the global pharmaceutical landscape is being redefined by a single, seismic force: the metabolic health revolution. At the epicenter of this transformation stands...

The Trillion-Dollar Pivot: Eli Lilly Unleashes Volume-Led Strategy to Cement Obesity Market Dominance in 2026

Topics Economy

January 06, 2026

As of January 6, 2026, the landscape of the pharmaceutical industry has been fundamentally reshaped by Eli Lilly and Company (NYSE:LLY), which recently became the first healthcare entity to surpass a...

Harvard’s CHIEF AI: The ‘Swiss Army Knife’ of Pathology Achieving 98% Accuracy in Cancer Diagnosis

Topics Economy

January 06, 2026

In a landmark achievement for computational medicine, researchers at Harvard Medical School have developed a "generalist" artificial intelligence model that is fundamentally reshaping the landscape of...

Via TokenRing AI

Topics Artificial Intelligence

The New Standard in Oncology: Harvard’s CHIEF AI Achieves Unprecedented Accuracy in Cancer Diagnosis and Prognosis

January 02, 2026

In a landmark advancement for digital pathology, researchers at Harvard Medical School have unveiled the Clinical Histopathology Imaging Evaluation Foundation (CHIEF) model, a "generalist" artificial...

Via TokenRing AI

Topics Artificial Intelligence

The RNAi Powerhouse: A Deep Dive into Alnylam Pharmaceuticals’ Path to the S&P 500

January 02, 2026

As the calendar turns to 2026, Alnylam Pharmaceuticals (Nasdaq: ALNY) stands at the threshold of a new era. Once a speculative pioneer in the arcane world of RNA interference (RNAi), the...

As of today, January 1, 2026, Abbott Laboratories (NYSE: ABT) stands as one of the most resilient and strategically diversified giants in the global healthcare landscape. While the broader market has...

Topics Economy Intellectual Property Stocks

The Evolution of a Healthcare Giant: Abbott Laboratories (ABT) 2026 Stock Feature

January 01, 2026

The Year-End Biotech Chill: Adaptive Biotechnologies Braces for J.P. Morgan Crucible Amid Market Sell-Off

Topics Economy Lawsuit World Trade

December 30, 2025

As the final trading days of 2025 wind down, the biotechnology sector finds itself caught in a paradoxical "bifurcated" squeeze. While the broader indices have touched record highs this year, a sharp...

Biopharma’s Year-End Rollercoaster: Mereo Plummets 90% as BioMarin Seals $4.8 Billion Amicus Deal

Topics Artificial Intelligence Economy Intellectual Property

December 29, 2025

The biopharmaceutical sector witnessed a dramatic surge in volatility today, December 29, 2025, as the industry careened toward the end of its strongest year in two decades. In a day defined by extreme...

The Trillion-Dollar Pharma: A Deep Dive into Eli Lilly’s (LLY) Dominance in the Weight-Loss Era

Topics ETFs Intellectual Property

December 25, 2025

As of December 25, 2025, the global pharmaceutical landscape has been fundamentally reshaped by a single entity: Eli Lilly and Company (NYSE: LLY). In a year defined by breakthrough medical treatments...

Shares of Novo Nordisk (NYSE: NVO) surged more than 8% in early trading on December 23, 2025, after the pharmaceutical giant secured a landmark FDA approval for its high-dose oral semaglutide, branded...

Topics Economy Government Intellectual Property

Novo Nordisk Stock Soars as "Wegovy Pill" Gains FDA Approval, Reshaping Obesity Market

December 23, 2025

FDA Approves Genentech’s Lunsumio VELO™ for Subcutaneous Use in Relapsed or Refractory Follicular Lymphoma

December 22, 2025

From Genentech

Trump Strikes New Drug-Price Deals With Roche, Novartis, Merck And Other Pharma Giants ↗

December 19, 2025

The deals expand the pricing program to most targeted drugmakers in exchange for temporary tariff relief.

Topics Government World Trade

Genentech Announces Agreement With U.S. Government

December 19, 2025

From Genentech

Novartis US Stock Rises On Reports Of White House Pricing Deal Due Friday — Roche Also In Talks ↗

December 17, 2025

The potential agreements would mark another step in Washington’s broader effort to reshape drug pricing.

Genentech’s Giredestrant Reduced Risk of Invasive Disease Recurrence or Death by 30% in ER-positive Early-Stage Breast Cancer

Topics Government World Trade

December 10, 2025

From Genentech

Genentech Presents Lunsumio Data Showing Potential Across Earlier Treatment Lines in Indolent and Aggressive Lymphomas

December 08, 2025

From Genentech

This hot biotech stock could have a lot more room to run.

Is Alnylam Pharmaceuticals a Millionaire Maker? ↗

December 07, 2025

Via The Motley Fool

Should You Buy This Biotech Stock That Just Gained 5% in 1 Day? ↗

November 30, 2025

The comeback may have begun.

Via The Motley Fool

Pharma Bro Martin Shkreli Shorts Olema Pharmaceuticals Stock ↗

November 18, 2025

"Pharma Bro' and notorious bear Martin Shkreli is shorting Olema Pharmaceuticals stock.

Via Benzinga

OLMA Stock Doubles After Roche Cancer Drug Trial Yields Positive Results ↗

November 18, 2025

Roche was evaluating Giredestrant as an adjuvant endocrine treatment for people with certain types of early-stage breast cancer.